Non-Hodgkin Lymphoma | Specialty

PI3K-Targeted Therapy for Follicular Lymphoma

June 29th 2016

Treatment of Follicular Lymphoma

June 29th 2016

Encouraging Early Data for Novel PI3K Inhibitors

June 29th 2016

Duvelisib in Relapsed/Refractory CLL

June 29th 2016

Role of PI3K-Targeted Therapy in CLL

June 29th 2016

Treating Chronic Lymphocytic Leukemia

June 29th 2016

Dr. Christian Gisselbrecht on Outcomes of Relapsed DLBCL

June 17th 2016

Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

Duvelisib Hits Endpoint But Misses Expectations in Phase II iNHL Study

June 17th 2016

Single-agent duvelisib demonstrated an overall response rate of 46% for patients with indolent non-Hodgkin lymphoma, which successfully met the primary endpoint for the phase II DYNAMO study but not investor expectations.

Obinutuzumab Approved in Europe for Follicular Lymphoma

June 16th 2016

The European Commission approved obinutuzumab (Gazyvaro, EU; Gazyva, US) for use in combination with bendamustine, followed by maintenance obinutuzumab, as a treatment for patients with follicular lymphoma who are refractory to or progress on a single-agent rituximab (MabThera) or rituximab-containing regimen.

Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's Lymphoma

June 11th 2016

​Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).

Upfront Obinutuzumab Delays Progression in Follicular Lymphoma

May 27th 2016

Combining obinutuzumab (Gazyva) with chemotherapy in the first-line setting significantly reduced the risk of disease progression versus rituximab (Rituxan) plus chemotherapy in patients with follicular lymphoma.

Dr. Leonard on Treating Relapsed Patients With Follicular Lymphoma

May 12th 2016

John P. Leonard, MD, medical oncology, Weill Cornell Medicine and New-York Presbyterian, discusses treatment considerations for relapsed patients with follicular lymphoma.

Combination Regimens on the Rise in Mantle Cell Lymphoma

May 6th 2016

Michael E. Williams, MD, discusses emerging regimens on the horizon in mantle cell lymphoma, the potential of BCL-2 inhibition, and whether chemotherapy can be removed entirely from the treatment landscape.

CHMP Recommends Approval of Obinutuzumab for Follicular Lymphoma

April 29th 2016

Obinutuzumab (Gazyva) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use for use in combination with bendamustine as a treatment for patients with follicular lymphoma who previously received chemotherapy.

Dr. Andre Goy Explains Marginal Zone Lymphoma

March 31st 2016

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.

Dr. John Leonard on Treatment Options for Relapsed Follicular Lymphoma

March 20th 2016

John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.

Genomics Help Customize Therapy in Non-Hodgkin Lymphoma

March 19th 2016

With the R-CHOP chemotherapy regimen considered the backbone of therapy for treatment-naïve patients with non-Hodgkin lymphoma, researchers are now delving further into the genome to pave the way for therapeutic improvements.

Novel Agents on Horizon for Follicular Lymphoma

March 18th 2016

A host of novel agents are on the horizon that could further improve the long-term outcomes experienced by patients with follicular lymphoma, particularly those with relapsed or refractory disease.

Frontline Ibrutinib Highly Effective Across Subgroups for Elderly Patients With CLL/SLL

March 18th 2016

Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

New Agents Transform Treatment of Non-Hodgkin Lymphoma

March 16th 2016

Mitchell Smith, MD, discusses advancements in the field of non-Hodgkin lymphoma.